Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
Opthea Discontinues Wet AMD Trials After Second Phase III Trial Misses Endpoint
Opthea announced March 31 its decision to discontinue development of sozinibercept (OPT-302) in wet age-related macular degeneration (AMD) after a second Phase III trial missed its primary endpoint...
2024 Ophthalmic Revenue Roundup for Harrow, Astellas, Iridex, and Xbrane
Nashville, Tennessee-based Harrow reported March 27 that its 2024 revenue was $199.6 million, a 53 percent increase over $130.2 million in 2023. The company generated record quarterly revenue in Q4...
US FDA Again Rejects Aldeyra’s Reproxalap for Dry Eye, Asks for Yet Another Symptom Trial
Aldeyra Therapeutics reported April 3 that the US FDA had once again issued a complete response letter rejecting the company’s new drug application (NDA) for topical reproxalap as a treatment for d...
Malvina Eydelman, MD, Named CEO of CCOI Organization
Longtime US FDA regulator and board-certified ophthalmologist Malvina Eydelman, MD, has stepped into a new role as chief executive officer of the Collaborative Community on Ophthalmic Innovation (C...
Alcon Introduces Clareon PanOptix Pro Trifocal IOL
Alcon on April 2 introduced its Clareon PanOptix Pro trifocal IOL, a next-generation version of its groundbreaking PanOptix model. The company said the PanOptix Pro had been made available to selec...
Sydnexis Receives Positive CHMP Opinion for Low-Dose Atropine Drops in Pediatric Myopia
Sydnexis announced April 1 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended marketing authorization in the European Union for its low-dose ...
Topcon to Go Private Through Tender Offer by KKR and JIC Capital
Publicly held Topcon plans to go private under a $2.3 billion tender offer by private equity firm KKR, headquartered in New York, and JIC Capital, the private equity arm of Japan’s government-owned...
Rayner Doubles IOL Manufacturing Capacity with Expansion of Facility
Rayner announced April 2 that it had completed an expansion of its production facility in Worthing, UK, doubling the number of intraocular lenses (IOLs) it can manufacture annually to 4 million. Th...
Aviceda Appoints Jeffrey Nau, PhD, MMS, as Chief Executive Officer
Aviceda Therapeutics announced April 1 that it had appointed Jeffrey Nau, PhD, MMS, as chief executive officer, effective immediately. Nau will also join the company’s board of directors, Aviceda s...
Bausch + Lomb Recalls Certain enVista IOLs Amid Reports of TASS Cases
Bausch + Lomb announced March 27 that it was voluntarily recalling certain intraocular lenses (IOLs) on its enVista platform. A letter to customers from Bausch + Lomb Chairman and CEO Brent Saunder...
Alcon Announces Majority Ownership of Aurion
Alcon announced March 26 that it had acquired a majority interest in Aurion Biotech, developer of a corneal cell therapy. News of Alcon’s majority stake—after acquiring additional shares in Aurion ...
Alcon Agrees to Buy Lensar in Deal Worth up to $430 Million
Alcon announced March 24 that it had entered into a definitive agreement to acquire Lensar, including its Ally femtosecond laser cataract system, its Streamline software, and the Lensar legacy lase...
Past News Stories
Opthea, Unity Candidates Miss Clinical Trial Endpoints vs. Aflibercept
Opthea and Unity Biotechnology reported results March 24 for their retinal treatment candidates that failed to meet or beat Regeneron’s Eylea (aflibercept) in clinical trials for wet AMD and DME, r...
Alcon Announces CE Mark Approval, European Launch of Clareon Vivity IOL
Alcon reported March 25 that the Clareon Vivity extended depth of focus (EDOF) intraocular lens (IOL) had received CE marking, along with the toric model, and will begin a commercial rollout in Eur...
Chinese Regulators Approve DORC’s ILM-Blue Ocular Dye
German company Carl Zeiss Meditec announced March 27 that China’s National Medical Products Administration (NMPA) had approved ILM-Blue ocular dye from DORC. The product is approved in the US as Ti...
Surrozen to Focus on Ophthalmic Pipeline, Raises up to $175 Million in Private Placement
Surrozen announced March 24 that it would focus on its ophthalmic pipeline, including the development of new treatment options for retinopathies. Concurrently, the company said that a private place...
Pantheon, Eyedeal Medical to Collaborate on Bioengineered Corneal Implant
Pantheon Vision announced March 27 that it would collaborate with Chinese ophthalmic device manufacturer Eyedeal Medical to advance the production and commercialization of Pantheon’s corneal implan...
Zeiss Launches Visulas Combi in Canada
Carl Zeiss Meditec announced March 21 the availability in Canada of the Visulas Combi, a green and YAG ophthalmic laser workstation combining photodisruption, photocoagulation, and slit lamp techno...
US FDA Expands Label for Iluvien to Include Chronic Non-infectious Posterior Uveitis
ANI Pharmaceuticals, of Baudette, Minnesota, announced March 14 that the US FDA had approved an expanded label for Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) to include treatment...
Chinese Regulators Approve Innovent’s Sycume for Thyroid Eye Disease
China’s Innovent Biologics announced March 14 that Chinese regulators had approved Sycume, a recombinant anti-insulin-like growth factor 1 receptor antibody for thyroid eye disease (TED). Innovent ...
Eyenovia Weighs Potential All-Stock Reverse Merger with Betaliq
Eyenovia, of New York, reported March 20 that it was contemplating an all-stock reverse merger with Betaliq, of Tampa, Florida. The new, publicly listed company would combine Betaliq’s EyeSol water...
Changes in NIH Grant Rules Threaten to Ripple Through Eye Disease Research
Any changes to the rules that accompany US government research grants could affect eye research in the US in a big way. The US government awards an average of $1.1 billion a year in grants to resea...
Thomas Panek to Lead Lighthouse Guild
Lighthouse Guild announced March 18 that it had appointed Thomas Panek as its new president and CEO, effective April 1. Panek replaces Calvin Roberts, MD, who has led the nonprofit since April 2020...
Xbrane to Sell Part of Company to Alvotech, Plans to Keep Ximluci
Sweden’s Xbrane will sell its Cimzia biosimilar candidate and parts of its organization to Iceland’s Alvotech for SEK 275 million ($27.1 million), the two companies reported March 20. Xbrane will r...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.